News reports on the Chinese Sinovac COVID-19 vaccine.
28 Feb 2021
Philippines receives Chinese vaccine (Sinovac), but Duterte prefers another brand…
www.reuters.com
11 April 2021
Chinese vaccines “don’t have very high protection rates”, said Gao Fu, the director of the China Centers for Disease Control.
Beijing has distributed hundreds of millions of doses in other countries.
www.aljazeera.com
11 April 2021
A COVID-19 vaccine developed by China’s Sinovac was found to have an efficacy rate of slightly above 50% in Brazilian clinical trials.
www.reuters.com
By comparison, the vaccine made by Pfizer-BioNTech has been found to be 97-percent effective.
Efficacy Rates from Yale Medicine.
Overall all risks.
95.0% Pfizer-BioNTech
94.1% Moderna
Against risk of symptomatic disease.
96.4% Novavax
76.0% Oxford-AstraZeneca
72.0% Johnson & Johnson
?% Pfizer-BioNTech
?% Moderna
Against risk of Severe Disease.
100% Oxford-AstraZeneca
100% Novavax
86.0% Johnson & Johnson
?% Pfizer-BioNTech
?% Moderna
Moderna: 94.1% effective at preventing symptomatic infection. 86.4% for people ages 65 and older.
Johnson & Johnson: 72% overall efficacy and 86% efficacy against severe disease.
Oxford-AstraZeneca: 76% effective at reducing the risk of symptomatic disease, and 100% against severe disease. 85% effective in preventing COVID-19 in people over 65.
Novavax: 96.4% efficacy in reducing mild and moderate disease, 100% against severe disease from the original strain of COVID-19.